Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quality by Design Crossing Threshold from Development to Manufacturing

This article was originally published in The Gold Sheet

Executive Summary

As quality by design goes commercial drug manufacturers struggle to translate concepts that made sense in the lab into processes that work in the manufacturing plant, they tell ISPE Washington conference PQLI session. The focus turns to training and communications challenges. FDA reviewers coach investigators on what to look for in a QbD inspection. Post-CMC pilot QbD applications roll in the door at FDA. The agency shares advice on crafting these submissions: Don't forget about 'residual risk.' Remember to maintain your design spaces. Keep in mind how the criticality determination process is evolving. Increasingly, design spaces are defined by models, but those models pose challenges to manufacturing equipment operators. The same goes for 'operationalizing' new QbD control strategies. The key: Get operations personnel involved.

You may also be interested in...



The Long Learning Curve For Artificially Intelligent Drug Manufacturing Begins Now

Drugmakers quickly adopt low-impact AI/ML models in quest to eventually automate manufacturing processes. Already, they are learning a lot about how these models can support their operations. One finding: innovative change management approaches may be required to unlock their full potential.

The Long Learning Curve For Artificially Intelligent Drug Manufacturing Begins Now

Drugmakers quickly adopt low-impact AI/ML models in quest to eventually automate manufacturing processes. Already, they are learning a lot about how these models can support their operations. One finding: innovative change management approaches may be required to unlock their full potential.

Anti-Counterfeiting Advances Regionally Despite Global Impasse

Counterfeits or substandard generics? Clash over definitions roils global anti-counterfeiting initiative. WHO IMPACT members divide over conflicting goals: protecting brands from counterfeits; protecting generics from being branded as counterfeits; and protecting emerging markets from substandard generics. Blowup over Dutch customs seizures. IMPACT begins to regroup as anti-counterfeiting regulatory landscape grows increasingly complex. U.S. pursues slow-tracked trace-and-trace; California e-pedigree stymied. The E.U. advances with pharmacy verification approach, registers a success with EFPIA pilot. Council of Europe works to criminalize counterfeit drugs. USP and AID minilabs would empower developing regulators. One third of antimalarials were substandard. Nigeria enables consumers to check for counterfeits by cell phone. Baxter takes layered approach. A pressing need for on-dose protection seen, but it must be covert. The day of mass serialization will arrive, but there will be no panacea.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS000389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel